Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $26.3 million.

  • Harmony Biosciences Holdings' Accounts Payables rose 15010.44% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year increase of 15010.44%. This contributed to the annual value of $13.7 million for FY2024, which is 2248.17% down from last year.
  • Latest data reveals that Harmony Biosciences Holdings reported Accounts Payables of $26.3 million as of Q3 2025, which was up 15010.44% from $28.3 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' Accounts Payables' 5-year high stood at $28.3 million during Q2 2025, with a 5-year trough of $1.0 million in Q4 2021.
  • Moreover, its 5-year median value for Accounts Payables was $6.9 million (2022), whereas its average is $11.1 million.
  • In the last 5 years, Harmony Biosciences Holdings' Accounts Payables tumbled by 6083.72% in 2021 and then surged by 36830.43% in 2023.
  • Over the past 5 years, Harmony Biosciences Holdings' Accounts Payables (Quarter) stood at $1.0 million in 2021, then soared by 278.22% to $3.8 million in 2022, then skyrocketed by 368.3% to $17.7 million in 2023, then dropped by 22.48% to $13.7 million in 2024, then skyrocketed by 91.65% to $26.3 million in 2025.
  • Its last three reported values are $26.3 million in Q3 2025, $28.3 million for Q2 2025, and $17.5 million during Q1 2025.